Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Teminioluwa Ajayi

Gastroenterology Humble, TX Medical Doctor

NPI 1649777210 CMS profile 11306034

18980 N Memorial Dr Ste 280, Ste 8A, Humble, TX 77338

Open in the dashboard

General payments

$7,223

130 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Teminioluwa Ajayi of Humble, TX is reported in the CMS Open Payments database as having received $7,223 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,315 49
2024 General $2,706 33
2023 General $626 32
2022 General $462 14
2021 General $114 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Teminioluwa Ajayi
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Teminioluwa Ajayi were reported at $3,315. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Teminioluwa Ajayi Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $114 $352 $106–$1,054 $132
2022 $462 $448 $129–$1,270 $149
2023 $626 $533 $150–$1,390 $160
2024 $2,706 $605 $160–$1,606 $164
2025 $3,315 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Olympus Corporation of the Americas $1,639 20 payments
  2. Boston Scientific Corporation $1,226 8 payments
  3. Medtronic, Inc. $1,055 20 payments
  4. Creo Medical Inc. $920 2 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $362 14 payments
  6. CONMED Corporation $320 8 payments
  7. AbbVie, Inc. $303 12 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $247 20 payments
  9. Janssen Biotech, Inc. $236 10 payments
  10. 3-D Matrix, Inc. $176 1 payment
  11. Other $738 15 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,686 109 payments
  2. Travel and Lodging $3,537 21 payments
Products named General payments · program years 2021–2025
  1. DISPOSABLE DISTAL ATTACHMENT $1,639 20 payments
  2. Olympus $1,127 8 payments
  3. Single Use Electrosurgical Knife KD-655 $967 14 payments
  4. Speedboat Ultraslim (SB1L) $920 2 payments
  5. CONMED GENERATORS $283 6 payments
  6. INTERSTIM $279 6 payments
  7. ENTYVIO $265 9 payments
  8. XIFAXAN $247 20 payments
  9. EndoFlip $213 2 payments
  10. CREON $195 6 payments
  11. Other $1,807 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$17,601

Medicare's payments for the services billed

Medicare patients

53

Average age 73

Services billed

181

29 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 72%
Diabetes 70%
Arthritis 62%
Ischemic heart disease 60%
Heart failure 53%
Atrial fibrillation 49%
Depression 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $149
$149 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $62
$62 — —
CREON
  • AbbVie, Inc. $38
$38 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $34
$34 — —
GATTEX
  • Takeda Pharmaceuticals U.S.A., Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record